Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States
SHANGHAI, China, April 22, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first …